Asset Classes

Free investment financial education

Language

Multilingual content from IBKR

Close Navigation
Learn more about IBKR accounts

Eli Lilly Enters the Chinese Market as Tirzepatide Gains Approval, Shares Gain

Posted July 19, 2024 at 9:30 am
Tim Fries
The Tokenist

Eli Lilly’s weight loss drug tirzepatide has received approval from Chinese regulators, intensifying competition with Novo Nordisk.

Eli Lilly and Company (NYSE: LLY) announced today that its weight loss drug tirzepatide has received approval from Chinese regulators.

This development marks a significant expansion for the pharmaceutical giant in the world’s second-largest economy, which is estimated to have the highest number of overweight or obese people globally. The approval intensifies competition with Novo Nordisk (NYSE: NVO) in the Chinese market following the June 2024 approval of Novo’s weight loss drug Wegovy.

Eli Lilly Gains Regulatory Approval in China for Weight Loss Drug

Tirzepatide, the active ingredient in Eli Lilly’s diabetes drug Mounjaro and weight-loss drug Zepbound, has gained regulatory approval in China.

The company made the announcement via social media, though no immediate details were provided regarding the commencement of sales or supply amounts. This approval adds to tirzepatide’s growing global presence, with previous approvals in the United States, European Union, Canada, Australia, and the United Kingdom for various indications, including type 2 diabetes treatment and weight loss management.

LLY Stock Sees Slight Gains in Premarket Trading on the News

Following the news, Eli Lilly’s stock (LLY) showed positive movement in pre-market trading. As of 8:00 AM EDT, the stock was trading at $867.98, up 2.25% from its previous close of $848.90. The company’s market capitalization stands at an impressive $764.35 billion, reflecting investor confidence in its growth prospects.

Eli Lilly has demonstrated strong financial performance, significantly outperforming the S&P 500 index. The stock has recorded a year-to-date return of 46.13%, a one-year return of 91.27%, and a remarkable five-year return of 752.79%.

Key financial metrics include a trailing P/E ratio of 125.02, an EPS of $6.79, and a profit margin of 17.08%. The company reported a trailing twelve-month revenue of $35.93 billion and a net income available to common shareholders of $6.14 billion.

As Eli Lilly continues to expand its global footprint in the weight loss drug market, investors and industry observers will closely watch the company’s performance in the competitive Chinese market. The approval of tirzepatide in China represents a significant milestone for Eli Lilly.

Originally Posted July 19, 2024 – Eli Lilly Enters the Chinese Market as Tirzepatide Gains Approval, Shares Gain

Disclaimer: The author does not hold or have a position in any securities discussed in the article.

Join The Conversation

If you have a general question, it may already be covered in our FAQs. If you have an account-specific question or concern, please reach out to Client Services.

Leave a Reply

Disclosure: The Tokenist

Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult a licensed financial advisor prior to making financial decisions.

Disclosure: Interactive Brokers

Information posted on IBKR Campus that is provided by third-parties does NOT constitute a recommendation that you should contract for the services of that third party. Third-party participants who contribute to IBKR Campus are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.

This material is from The Tokenist and is being posted with its permission. The views expressed in this material are solely those of the author and/or The Tokenist and Interactive Brokers is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to buy or sell any security. It should not be construed as research or investment advice or a recommendation to buy, sell or hold any security or commodity. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

IBKR Campus Newsletters

This website uses cookies to collect usage information in order to offer a better browsing experience. By browsing this site or by clicking on the "ACCEPT COOKIES" button you accept our Cookie Policy.